Skip to content
Clinical Trials – home

Diabetic retinal oedema Diagnostics

4 / 13 trials open to patients13 countries

In short

Diabetic retinal oedema is a serious eye complication that develops when high blood sugar damages the tiny blood vessels in the back of the eye, causing fluid to leak and accumulate in the macula. This swelling in the central part of your retina can blur your vision and, without proper care, lead to significant vision loss. Understanding when and how to get tested can make all the difference in protecting your sight.

Key points

  • Regular annual eye exams are your best defense—diabetic retinal oedema often develops silently without symptoms until vision is already affected
  • Your risk increases dramatically the longer you've had diabetes, with about 90% of type 1 diabetes patients showing some retinal changes after 10 years
  • Optical coherence tomography scans can detect retinal swelling thinner than a human hair, catching problems before you notice them
  • Sudden changes in vision—like dark spots appearing first thing in the morning or straight lines looking bent—warrant immediate medical attention
  • Even with multiple treatments, diabetic macular oedema persists in up to 65% of patients, highlighting why early detection matters so much
  • Controlling blood sugar is just as important as medical treatments—eye injections only provide temporary relief without addressing the root cause
  • Nerve damage to your retina from prolonged swelling is irreversible, making prompt treatment critical for preserving vision
  • Clinical trials often use highly specific diagnostic criteria, requiring precise measurements of retinal thickness and detailed documentation of your diabetes history

Introduction: Who Should Seek Testing and When

If you have diabetes, you are automatically at risk for developing diabetic retinal oedema, also called diabetic macular edema. This condition doesn't usually announce itself with pain or obvious warning signs in its early stages. Many people discover they have it during a routine eye examination before they even notice vision problems. That's why regular eye testing is not just recommended—it's essential for anyone living with diabetes.

You should seek diagnostic testing right away if you notice sudden changes in your vision. Warning signs include blurred or wavy vision, dark spots appearing in your field of view (especially first thing in the morning), difficulty reading, colors appearing faded or washed out, straight lines that look bent or curved (like door frames or lamp posts), trouble seeing in bright light or glare, or objects that seem to change size when you switch from viewing with one eye to the other. Any of these symptoms warrants immediate contact with your eye care provider.

Even if you have no symptoms at all, you need to have your eyes checked regularly. People with diabetes should attend annual diabetic eye screening appointments to reduce their risk of vision loss. If you've been diagnosed with diabetic retinopathy—damage to the blood vessels in your retina caused by diabetes—you may need more frequent examinations, as diabetic retinal oedema is a complication of this condition.

If you're pregnant and have diabetes—or develop gestational diabetes during pregnancy—your healthcare team may recommend additional eye examinations throughout your pregnancy. Pregnancy can increase the risk of developing diabetic retinal problems or make existing problems worse.

Diagnostic Methods for Identifying Diabetic Retinal Oedema

You cannot see swelling in your own retina just by looking in the mirror, but your eye care specialist can detect it during a thorough examination. This is one of the most important reasons to keep your regular eye exam appointments, especially when you have diabetes.

The diagnostic process typically begins with a comprehensive eye examination. Your eye care provider will start by checking your visual acuity—how well you can see at various distances. This simple test measures whether your vision has changed and by how much.

A critical part of diagnosing diabetic retinal oedema involves dilating your pupils. Your doctor will place special drops in your eyes that widen your pupils, allowing them to get a much better view of the structures inside your eye, particularly your retina and macula. The drops can make your near vision blurry for several hours, so it's wise to bring someone along to drive you home after the appointment.

During the dilated examination, your provider will use a slit lamp—a specialized microscope with a bright light—to examine the inside and outside parts of your eyes. They'll look for irregularities in your retina and signs that fluid has accumulated in the macula.

Beyond the basic eye exam, several specialized imaging tests help diagnose and monitor diabetic retinal oedema. One of the most important is optical coherence tomography, commonly called OCT. This painless imaging test creates detailed cross-sectional pictures of your retina, showing its anatomy and thickness. The OCT reveals exactly how much fluid, if any, has leaked into the retinal tissue. It works somewhat like an ultrasound but uses light waves instead of sound waves. Later, your doctor can use follow-up OCT scans to check whether treatment is working by comparing the thickness of your retina over time.

Another valuable test is fluorescein angiography. After your eyes are dilated, your doctor injects a special yellow-orange dye called fluorescein into a vein in your arm. As the dye circulates through your bloodstream, it travels to the blood vessels in your eyes. A specialized camera takes pictures as the dye moves through these vessels, highlighting areas where blood vessels are closed, broken, or leaking fluid. These pictures help your doctor pinpoint exactly which blood vessels are damaged and causing the fluid buildup in your macula.

Your provider may also use an Amsler grid test, which uses a pattern of horizontal and vertical lines to check your central vision. When you look at the grid, you'll be asked to describe what you see. If you have diabetic retinal oedema, the straight lines may appear wavy, distorted, or broken.

These diagnostic tests work together to give your doctor a complete picture of what's happening inside your eye. The comprehensive eye exam reveals whether you have diabetic retinal oedema, while the imaging tests show how severe it is and which specific areas are affected. This information is crucial for determining the best treatment approach and tracking whether the condition is improving, staying stable, or getting worse over time.

Diagnostics for Clinical Trial Qualification

When patients with diabetic retinal oedema are being considered for enrollment in clinical trials, researchers use specific tests and criteria to determine who qualifies. While the exact requirements vary from one study to another, certain standard diagnostic procedures are commonly used to establish eligibility.

Visual acuity testing is typically a key qualification criterion. Clinical trials often specify that participants must have vision within a certain range—for example, vision of 20/50 or worse in the affected eye. This ensures the study includes patients who have meaningful vision loss that could potentially improve with treatment. Researchers measure visual acuity using standardized charts and protocols to ensure consistent measurements across all participants.

Optical coherence tomography scans are standard tools for trial qualification because they provide objective, measurable data about retinal thickness. Researchers can use OCT to measure exactly how much swelling is present in the macula and track changes over time with great precision. Many clinical trials set specific thresholds for retinal thickness—participants must have swelling that exceeds a certain measurement to qualify. The OCT also helps researchers identify and exclude patients who have other eye conditions that might interfere with the study results.

Fluorescein angiography is another diagnostic test frequently used in clinical trial screening. This test helps researchers confirm that fluid leakage is occurring and identify the pattern and severity of blood vessel damage. The detailed images from fluorescein angiography allow researchers to classify patients according to the type and extent of their diabetic retinal disease, which is important for matching patients to appropriate studies.

In addition to eye-specific tests, clinical trials typically require documentation of a patient's diabetes diagnosis and history. Researchers need to know how long someone has had diabetes, what type of diabetes they have (type 1 or type 2), and how well controlled their blood sugar levels are. Blood tests measuring hemoglobin A1c—a marker of average blood sugar over the past few months—are commonly part of the screening process.

The diagnostic process for trial qualification is usually more extensive than a regular eye exam. Researchers need detailed baseline information about each participant's condition before treatment begins, so they can accurately measure any changes that occur during the study. This often means repeating some tests multiple times to establish consistent baseline measurements.

Prognosis and Survival Rate

Prognosis

The outlook for people with diabetic retinal oedema has improved significantly with advances in treatment. When caught early and treated appropriately, many patients can maintain their vision or even experience improvements. However, the prognosis depends heavily on several factors, including how quickly the condition is diagnosed, how well blood sugar and blood pressure are controlled, and how promptly treatment begins.

Unfortunately, not everyone responds equally well to treatment. Research shows that even after multiple treatments with newer medications like anti-VEGF injections, diabetic retinal oedema persists in approximately 31.6% to 65.6% of patients. Some people require frequent, ongoing treatments to prevent vision loss, while others achieve more stable results.

One of the most important factors affecting prognosis is blood sugar control. Proper management of diabetes is essential because the treatments for diabetic retinal oedema have temporary effects—they address the symptoms but don't solve the underlying problem until blood sugar is properly controlled. Patients who successfully manage their blood sugar levels, blood pressure, and cholesterol have better outcomes and may even be able to avoid starting a series of eye injections.

It's crucial to understand that if diabetic retinal oedema leads to damage of the neural cells and nerve fibers in the retina, these changes are irreversible. Neuronal cell death and axonal degeneration can result in permanent visual loss. This is why treating the swelling before significant neural damage occurs is essential for preserving vision. Early detection through regular eye screenings gives patients the best chance of protecting their sight.

Survival rate

Diabetic retinal oedema itself is not a life-threatening condition and does not affect survival rates. However, it serves as an important indicator of the broader effects of diabetes on the body. When someone develops vision problems from diabetes, it often means that blood vessels in other parts of the body may also be damaged. People with diabetic retinal oedema should ensure they're receiving comprehensive care for all potential diabetes complications, including heart disease, kidney disease, and nerve damage, as these conditions can affect overall health and longevity.

Did you know?

  1. About 1 in 14 people with diabetes eventually develops diabetic macular edema, making it one of the most common causes of vision loss in diabetic patients—yet many have no symptoms in the early stages when treatment works best.[1]
  2. The special dye used in fluorescein angiography is bright yellow-orange and temporarily colors your skin and urine until your body clears it out over several hours—it's completely harmless but can be startling if you're not expecting it.[8]
  3. Optical coherence tomography uses light waves similar to ultrasound but creates images with resolution so fine that doctors can see individual layers of your retina that are thinner than a human hair.[8]

Questions people often ask

This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.

Clinical trials for Diabetic retinal oedema

Recruiting trials first

See all 13 trials →
Quick filters

13 clinical trials in this condition

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Alvotech Swiss AG
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Faricimab
  • Sponsor:Martin-Luther-Universitaet Halle-Wittenberg
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Boehringer Ingelheim International GmbH
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Centre Hospitalier Universitaire De Dijon
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyepoint Inc.
Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyepoint Inc.
See all 13 trials →filters applied: condition = Diabetic retinal oedema

Related conditions in the same therapeutic area

Back to all diseases
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).